Malik Fady Ibraham 4

What Happened

• Malik Fady Ibraham, EVP Research & Development at Cytokinetics, exercised 3,500 stock options (exercise price $7.80) on 2026-07-21 (cost $27,300) and sold the 3,500 resulting shares the same day in an open-market sale at $80.59 per share for gross proceeds of $282,065. The net proceeds after the exercise cost are about $254,765. The filing also records the conversion/termination of the derivative instrument at $0.

Key Details

• Transaction date: 2026-07-21; Form 4 filed: 2026-07-23 (within the typical 2-business-day window).
• Exercise: 3,500 shares at $7.80 each = $27,300 (code M, acquired).
• Sale: 3,500 shares at $80.59 each = $282,065 (code S, disposed).
• Derivative disposition: 3,500 (code M, $0) — reflects conversion/termination of the option position.
• Shares owned after transaction: not specified in the excerpt provided.
• No 10b5-1 plan or tax-withholding note was provided in the supplied details.

Context

• This was an exercise followed by an immediate sale (a cashless exercise pattern): options were exercised and the shares were sold the same day. Sales by executives are common and do not on their own indicate a change in company outlook. Purchases typically carry more weight when assessing insider sentiment.